Human LDL Receptor Enhances Sequestration of ApoE4 and VLDL Remnants on the Surface of Hepatocytes but Not Their Internalization in Mice by Altenburg, M. et al.
Human LDL Receptor Enhances Sequestration of ApoE4 and 
VLDL Remnants on the Surface of Hepatocytes but Not Their 
Internalization in Mice
Michael Altenburg, Jose Arbones-Mainar, Lance Johnson, Jennifer Wilder, and Nobuyo 
Maeda
Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel 
Hill
Abstract
Objective—In humans, apolipoprotein (apo) E4 is associated with elevated plasma cholesterol 
levels and a high risk of developing atherosclerosis, whereas apoE2 is protective. Here we 
investigate the mechanism by which mice expressing human apoE isoforms recapitulate this 
association when they also express high levels of human low-density lipoprotein receptor (LDLR).
Methods and Results—Primary hepatocytes from apoE4 mice secreted less apoE into the 
medium than hepatocytes from apoE2 mice. Increased LDLR expression decreased this secretion 
and increased degradation of apoE4. An apoE4-GFP fusion protein expressed in the liver of apoE-
deficient mice accumulated on the hepatocyte surface bordering the space of Disse in an LDLR-
dependent manner. Fluorescence-labeled very low–density lipoprotein (VLDL) remnants 
accumulated on the hepatocyte surface in apoE4 mice with high LDLR, but they were internalized 
poorly. In contrast, apoE2-GFP did not accumulate on the hepatocyte surface even when the 
LDLR expression was high, but apoE2 mice with high LDLR internalized the remnants avidly 
without sequestering them on the hepatocyte surface.
Conclusions—The high affinity of apoE4 to the LDLR enhances VLDL sequestration on the 
hepatocyte surface but delays their internalization. This delay likely increases VLDL conversion to 
cholesterol-enriched remnants in apoE4 mice with high LDLR, and probably to LDL in humans 
with apoE4.
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A polipoprotein E (apoE) and the low-density lipoprotein receptor (LDLR) play a pivotal 
role in the clearance of lipoproteins by the liver, thereby reducing plasma cholesterol, a 
leading determinant of atherosclerosis susceptibility.1,2 Uptake of triglyceride-rich 
lipoproteins (TRL) occurs via multiple receptors and perhaps in several steps.3 The first, 
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most important step appears to be the sequestration of TRL on the microvilli of hepatocytes, 
where LDLR, heparan sulfate proteoglycans (HSPG), and LDLR related proteins (LRP) are 
located. These molecules bind apoE proteins secreted by the liver thereby serving as 
reservoirs for enriching remnant particles with apoE.4 They also serve as the receptors for 
internalization of apoE-enriched remnants.3
In humans, the Apoe gene is polymorphic, resulting in production of 3 common isoforms, 
apoE2, E3, and E4. They differ in primary structure at 2 positions, E2 having Cys at both 
positions 112 and 158, E3 having a Cys at 112 and an Arg at 158, and E4 having Arg at both 
positions. They also differ in their LDLR binding affinity; apoE4 binds LDLR with a 
slightly higher affinity than apoE3, whereas apoE2 has much reduced binding compared to 
the other 2 isoforms.5–9 Despite the low receptor binding of apoE2, the majority of 
individuals carrying apoE2 have lower plasma LDL cholesterol and reduced atherosclerosis 
risk, although 5% to 10% of apoE2 homozygotes develop type III hyperlipoproteinemia 
characterized by markedly elevated plasma lipid levels.2,10 Equally paradoxical is the 
association of the apoE4 isoform with high LDL-cholesterol, low plasma triglycerides (TG), 
and an increased risk of atherosclerosis.1,2,10–14 How the different apoE isoforms lead to 
different plasma lipoprotein profiles in vivo remains unclear, and mice with the wild-type 
Apoe gene replaced with human alleles do not simply replicate human phenotypes. Thus, all 
mice expressing apoE2 (Apoe2/2) exhibit type III hyperlipoproteinemia and develop 
atherosclerosis even on a normal chow containing low cholesterol and low fat, whereas those 
expressing apoE3 (Apoe3/3) or apoE4 (Apoe4/4) are normolipidemic and do not develop 
atherosclerosis.7,15,16 However, the human-like associations are replicated when the mice 
expressing human apoE isoforms also have 2- to 3-fold normal LDLR expression 
attributable to the Ldlr*h allele coding for human LDLR.17–20 Both adenovirus-mediated or 
global overexpression of the human LDLR in mice with apoE2 results in reduction of 
plasma cholesterol and TG and the absence of atherosclerosis.17,21 Mice with human apoE3 
and the Ldlr*h allele (Apoe3/3Ldlrh/+) have significantly decreased HDL-cholesterol but 
only a small increase in remnants and do not develop atherosclerosis.18 In contrast, on a 
high-fat Western type diet, mice with apoE4 overexpressing the LDLR (Apoe4/4Ldlrh/+) 
have increased plasma very low density lipoproteins (VLDL)/chylomicron remnants, 
decreased HDL-cholesterol levels, and develop atherosclerosis.18
The present work was aimed to test the hypothesis that the adverse effects of the increased 
LDLR expression in mice with apoE4 is because the higher affinity of apoE4 for the LDLR 
inhibits enrichment of apoE4 on apoE-poor VLDL. We show that a substantial amount of 
apoE4, and to a lesser extent apoE3, but not apoE2, is colocalized with LDLR on the surface 
of hepatocytes. This interaction with the LDLR increases the association of apoE4 with 
hepatocytes, limits apoE4 secretion, and enhances its degradation in primary cultured 
hepatocytes. It also enhances the sequestration of VLDL remnants on the hepatocyte surface, 
but not their internalization.
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ApoE-deficient mice (Apoe−/−), LDLR-deficient mice (Ldlr−/−), mice homozygous for 
replacement of the mouse apoE gene with either the human APOE*2, APOE*3, or APOE*4 
allele (Apoe2/2, Apoe3/3, and Apoe4/4), and mice overexpressing the human LDLR minigene 
(Ldlrh/+) were individually backcrossed at least 6 generations to C57BL/6 genetic 
background.7,15–17 Intercross of these mutants produced mice with various combinations of 
the Apoe and Ldlr loci. Mice were fed a high-fat Western-type diet (HFW) containing 21% 
(wt/wt) fat and 0.2% (wt/wt) cholesterol (TD88137; Teklad) for at least 2 weeks before 
experiments. Genotype and lipid profiles of experimental mice are presented in 
supplemental Table I and supplemental Figure I (available online at http://
atvb.ahajournals.org). The animals were handled under protocols approved by the 
Institutional Animal Care and Use Committees of the University of North Carolina-Chapel 
Hill. For additional details on methods, please refer to the supplemental materials (available 
online at http://atvb.ahajournals.org).
35S Labeling of Primary Mouse Hepatocytes
Primary hepatocytes were isolated as described.22 The cells were plated onto 60-mm mouse 
collagen IV-coated dishes (Falcon) and pulsed with 0.5 mL medium containing 35S 
methionine (100 μCi/mL, Amersham) for 30 or 60 minutes, and chased for 1 and 4 hours 
with fresh medium with excess cold methionine. ApoE was immunoprecipitated using a goat 
antihuman apoE antibody (Calbiochem), separated by SDS-PAGE, and visualized by a 
Fla-3000 phosphoimager (FujiFilm).
Adenoviruses
The plasmid vectors containing cytomegalus viral promoter-driven cDNA for fusion 
proteins, apoE2-GFP, apoE3-GFP, and apoE4-GFP, were provided by Dr Robert DeKroon at 
Duke University (Durham, NC). These vectors express fusion proteins with EGFP 
(enhanced green fluorescent protein) attached to the C-terminal end of each apoE isoform.23 
Adenoviral vectors encoding apoE2-GFP, apoE3-GFP, and apoE4-GFP were made using the 
AdEasy adenoviral system (Stratagene). Recombinant adenovirus stock, stored at −80°C, 
was diluted with PBS and 1×109 PFU in 0.2 mL of adenovirus was injected into each mouse 
via the tail vein.
Isolation, DiI Labeling, and Injection of VLDL
The VLDL fraction was isolated from pooled plasma by ultracentrifugation at d <1.006 
g/mL and labeled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate 
(DiI C18; Molecular Probes Inc), as described by Stephan and Yurachek.24 DiI-labeled 
VLDL (100 μg protein) was injected into tail veins of mice and livers were fixed with 4% 
paraformaldehyde 20 minutes later. DiI-labeled VLDL remaining in the plasma at 2 minutes, 
10 minutes, and 20 minutes was determined using a microscope fluorometer (Olympus 
FV500 with a SPOT 2 digital camera) using a modification of the fluorometric procedure 
described.25
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Livers were perfused through the portal vein at 2 mL/min for 2 minutes with 4% 
paraformaldehyde, excised from animals, and further fixed overnight in 4% 
paraformaldehyde. Slides with consecutive liver paraffin sections (5 μm) were used for 
immunohistochemistry. For confocal analysis 100-μm-thick liver sections were cut with a 
vibratome.
Statistical Analysis
The significance of differences between means was determined by use of 1-way ANOVA 
and Turkey-Kramer honestly significant difference tests (JMP software; SAS Inc).
Results
Secretion, Synthesis, and Degradation of ApoE in Primary Hepatocytes
To determine the cellular metabolism of the different apoE isoforms, we isolated primary 
hepatocytes from mice expressing different apoE isoforms and compared the apoE protein 
using Western blot analysis. After culturing in DMEM without FBS for 24 hours, primary 
hepatocytes from Apoe2/2 mice secreted more apoE protein into the medium compared to 
the cells from Apoe4/4 mice (Figure 1A). The ratio of medium apoE to cell-associated apoE 
in the Apoe2/2 cells was twice as high as those of Apoe3/3 or Apoe4/4 cells (Figure 1C). In 
addition, the level of LDLR expression affected the amount of apoE secreted from the 
cultured primary hepatocytes (Figure 1A). The ratio of medium apoE to cell-associated apoE 
in the cultured Apoe4/4Ldlrh/± hepatocytes was significantly lower than in Apoe4/4 cells 
(Figure 1C). In turn, the ratio in hepatocytes lacking LDLR (Apoe4/4 Ldlr−/−) expression 
was significantly higher than in Apoe4/4 hepatocytes (Figure 1C). Heparinase treatment 
increased apoE4 in the medium in both Apoe4/4Ldlrh/+ and Apoe4/4 hepatocytes, but the 
apoE4 secretion from the Apoe4/4Ldlrh/+ remained significantly depressed (Figure 1D). 
These data indicate that the relative amount of apoE secretion from the liver is inversely 
related to the affinity of the isoforms to the receptor as well as to the levels of LDLR 
expression.
The ratio of extracellular to cell-associated apoE amounts is likely determined by the uptake, 
but could also be attributable to changes in apoE synthesis or degradation. To determine how 
the LDLR expression levels affect production and degradation of apoE, we used a pulse 
chase system in primary hepatocytes isolated from Apoe4/4 and Apoe4/4Ldlrh/+ mice. The 
synthesis during a 30 minute (Figure 1E) pulse was not significantly different between 
Apoe4/4 (pixel intensity of 150.2±12.4) and Apoe4/4Ldlrh/+ (144.8±5.1) hepatocytes, 
indicating that a 2.5× higher LDLR expression had no effect on the apoE production rate. 
Cell-associated apoE retained after a 1-hour chase was more in Apoe4/4Ldlrh/+ cells than in 
Apoe4/4 cells, but they were not significantly different at 4 hours. However, consistent with 
the observation described above, apoE4 secreted from Apoe4/4Ldlrh/+ cells into the medium 
was significantly less than that from Apoe4/4 cells. The sum of the secreted and cell-retained 
apoE4 in Apoe4/4 and Apoe4/4Ldlrh/+ cells was 81% and 84% at 1 hour and 61% and 44% at 
4 hours, respectively, of the initial synthesis suggesting that an elevated LDLR expression 
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also increases apoE4 degradation. The results of experiments with a 60 minute pulse were 
very similar (supplemental Figure II).
Localization of ApoE Isoforms in the Liver
Immunostaining with an antibody against huLDLR illustrated the sinusoidal localization of 
the huLDLR in the liver sections of Apoe4/4Ldlrh/+ but not in Apoe4/4 mice (Figure 2A, 2B, 
and supplemental Figure III). ApoE4 colocalized with the LDLR in the Apoe4/4Ldlrh/+ liver 
as highlighted by the very intense staining of sinusoids with antibody against human apoE 
(Figure 2D). In contrast, apoE4 staining in the Apoe4/4 liver was diffuse and also present in 
the cytoplasm in a punctated pattern (Figure 2C). Very similar staining patterns were 
observed in the livers of Apoe3/3 and Apoe3/3Ldlrh/+ mice (Figure 2E and 2F), except that 
the sinusoidal staining relative to cytoplasmic staining was less intense in the Apoe3/3Ldlrh/+ 
liver than in the Apoe4/4Ldlrh/+ liver. This suggests that the LDLR levels influence 
sinusoidal localization of apoE4 and, to a lesser extent, of apoE3. Apoe2/2 and 
Apoe2/2Ldlrh/+ livers both had more pronounced intrahepatic staining than other apoE 
isoforms (Figure 2G and 2H), and the Apoe2/2Ldlrh/+ liver had more intracellular staining 
than the Apoe2/2 liver with no increase in sinusoidal staining. Total LDLR proteins in the 
membrane fraction of Ldlrh/+ livers detected by Western blots with antibodies specific for 
human or mouse LDLRs were similar regardless of apoE isoforms (supplemental Figure 
IV). Absolute amount of each LDLR was not determined.
To confirm the hepatic localization of apoE isoforms and the effect of increased LDLR 
without using antibodies, we injected Ad-apoE4-GFP, Ad-apoE3-GFP, and Ad-apoE2-GFP 
into Apoe−/− mice. ApoE-GFP fusion proteins appear to function normally and retain 
isoform specific characteristics as all lowered cholesterol levels in Apoe−/− mice 
(supplemental Figure V). Using confocal microscopy of the liver sections stained with 
Alexafluor633-labeled lectin to demarcate liver sinusoids, endothelial cells, and the space of 
Disse (SD),26 the apoE-GFP fusion proteins were visible as bright green hepatocytes with 
perinuclear concentration in the cytoplasm of 70% to 80% of the cells (Figure 3A through 
3F). Notably, apoE4-GFP and apoE3-GFP also demarked sinusoids. Inspection under a 
higher magnification revealed that GFP and Alexafluor633 labeled lectin signals were not 
overlapping (supplemental Figure VI), suggesting that the accumulation of apoE4-GFP is 
subendothelial in the SD, likely on the hepatocyte surface. The subendothelial accumulation 
of apoE4-GFP or apoE3-GFP was more pronounced in the liver of the Apoe−/−Ldlrh/h mice 
injected with Ad-apoE4-GFP or Ad-apoE3-GFP (Figure 3A and 3B). In marked contrast, 
Ad-apoE2-GFP showed little accumulation of apoE2-GFP on the hepatocyte surface even in 
the Apoe−/−Ldlrh/h mice (Figure 3C). These data demonstrate that the in vivo accumulation 
of apoE in the SD is dependent on its affinity to the LDLR and the expression levels of the 
LDLR.
Neither immunostaining nor Ad-apoE-GFP expression allows us to dissociate whether apoE 
accumulating on the hepatocyte surface is newly synthesized by the hepatocyte or originates 
from lipoproteins in circulation. However, we note that not all the cells demarcated by 
intense sinusoidal apoE-GFP signals have strong intracellular GFP signals. This suggests a 
substantial part of the apoE-GFP may be derived from apoE-GFP synthesized by other 
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transfected hepatocytes. To confirm this, we isolated VLDL fractions enriched with apoE2-
GFP or apoE4-GFP from Apoe−/−Ldlr−/− mice 5 days after transfection with the Ad-apoE2-
GFP or Ad-apoE4-GFP, and injected them into Apoe−/−Ldlrh/h mice. When livers were 
examined under confocal microscopy 5 minutes after the injection through tail veins, apoE4-
GFP was already localized on hepatocyte surfaces (Figure 3G). This suggests that 
lipoproteins that acquire apoE4 during the circulation can accumulate in the SD very 
efficiently. In contrast, very little apoE2-GFP was accumulated on the hepatocyte surface 
during this time (Figure 3H).
Sinusoidal Sequestration of ApoE and Internalization of Lipoprotein Remnants
The striking differences in the cellular localizations of the different apoE isoforms in the 
livers of mice with high levels of LDLR expression raise a question regarding the 
physiological relevance of apoE accumulated on the sinusoidal surface to remnant clearance. 
We therefore examined how the apoE isoforms affect plasma VLDL clearance and liver 
uptake by injecting DiI-labeled Apoe−/− VLDL into Apoe2/2, Apoe2/2Ldlrh/+, 
Apoe3/3Ldlrh/+, and Apoe4/4Ldlrh/+ mice. Decay of DiI-labeled Apoe−/− VLDL particles 
from plasma showed that the Apoe2/2 mice had the slowest clearance of Apoe−/− VLDL 
(Figure 4A). The clearance in the Apoe2/2Ldlrh/+, Apoe3/3Ldlrh/+, and Apoe4/4Ldlrh/+ mice 
were not different at 10 minutes after injection. However, the VLDL was removed from 
circulation during the next 10 minutes significantly faster in the Apoe2/2Ldlrh/+ mice than in 
both Apoe3/3Ldlrh/+ and Apoe4/4Ldlrh/+mice. At 20 minutes after injection, DiI-VLDL was 
barely detectable in the liver of Apoe2/2 mice (Figure 4B), but was avidly internalized in the 
Apoe2/2Ldlrh/+ liver (Figure 4C). Most of the signal was intracellular and surface-bound DiI-
VLDL was negligible (arrow, SD). In marked contrast, strong DiI-signal was on the hepatic 
surface of the Apoe4/4Ldlrh/+ liver (arrow, SD), whereas intracellular DiI-VLDL was less 
than in the Apoe2/2Ldlrh/+ liver (Figure 4C and 4E). Heparinase treatment of the 
Apoe4/4Ldlrh/+ mice 5 minutes before the injection of DiI-VLDL did not alter the 
localization of apoE and VLDL appreciably (supplemental Figure VII).
The reduced ability to internalize VLDL by the liver was associated with the accumulation 
of cholesterol-rich but apoE-poor VLDL remnants and 10-fold less total apoE in the plasma 
of Apoe4/4Ldlrh/+ mice compared to the Apoe2/2Ldlrh/+ mice (Figure 4B through 4E, lower 
panels). Plasma apoprotein to lipid ratios indicate that the Apoe2/2Ldlrh/+ mice have the 
most apoE enriched lipoproteins in all subclasses. Consistent with their higher HDL-C, 
Apoe2/2Ldlrh/+ mice also had more plasma apoA1 than Apoe4/4Ldlrh/+ mice, but the ratios 
of cholesterol to apoA1 in the HDL particles in these mice were not different. Hepatic 
expression of apoE, LRP, and SRB-1 that could influence lipid/cholesterol flux were not 
significantly different among experimental mice (supplemental Figure VIII).
Taken together, these data demonstrate that apoE2, which is elevated in the plasma on 
circulating lipoproteins and minimally associated with the hepatocyte surface, can facilitate 
internalization of apoE−/− VLDL remnants in the mice expressing a high level of LDLR. In 
contrast, apoE4 that is accumulated on the hepatocyte surface appears to enhance 
sequestration of VLDL remnants, but has only a limited capacity to participate in the 
internalization of lipoprotein remnants.
Altenburg et al. Page 6














There is little debate that the LDLR is important for clearance of remnant lipoproteins under 
normal physiological conditions, and that this process is mediated by the high-affinity 
binding of multiple apoE proteins on a lipoprotein particle to the LDLR.3 However, the 
common apoE isoforms in humans having affinities for the LDLR in the order of 
apoE4>apoE3>apoE2 significantly impact plasma cholesterol levels in an inverse order in 
humans and in mouse models.2,10,13,14,17,18,27 Our current study using humanized mice 
provides evidence that the extent of localization of the human apoE-isoforms in the liver 
inversely correlates with their efficacy in lipoprotein remnant internalization in vivo.
Previous studies have demonstrated the presence of apoE immunoreactivity along the 
sinusoidal front of hepatocytes together with some punctate cytoplasmic staining in the liver 
of wild type rats and mice.4,28,29 Studies have also shown that apoE is clustered on 
hepatocyte microvilli projecting into the space of Disse of the rat liver,28 and are used for 
hepatic endocytosis of remnants.4 Also, liver-derived and localized apoE has been shown to 
be more effective than nonhepatic derived apoE in the receptor-mediated internalization of 
remnants by the liver.30–32 Similarly, Linton et al showed in the space of Disse of the 
Apoe−/−Ldlr−/− mice that received wild-type bone marrows that an intense immunoreativity 
for extrahepatic apoE was present on the cell surface but cytoplasmic staining was not 
detected, indicating that no uptake of apoE-containing lipoproteins was occurring.29 These 
observations, using wild-type rodent apoE, clearly underscore the important role of apoE 
localized in the sinusoids of the liver in remnant uptake.
Multiple experiments have also shown that a substantial amount of apoE internalized with 
TRLs by the liver are recycled back to the cell-surface and resecreted, and that this 
resecretion is isoform specific.33–35 Considering that apoE4 and apoE3 have a higher affinity 
to the LDLR, our results showing enhanced accumulation of apoE4 and apoE3 in the space 
of Disse compared to apoE2 in mice overexpressing the human LDLR are not surprising. 
Although absolute amount of LDLR protein in the liver in these mice has not been 
determined, previous experiments by us and by others have unequivocally shown that the 
increases in LDLR expression lead to lowering of plasma cholesterol in mice.36,37 
Surprisingly, this surface sequestration of apoE4 does not directly translate to enhanced 
internalization of VLDL remnants into the cells. Thus, we observed that internalization of 
DiI-labeled VLDL was slower in the Apoe4/4Ldlrh/+ mice than in the Apoe2/2Ldlrh/+ mice. 
Remarkably, there were no indications that the increased LDLR enhances either LDLR-
mediated or LDLR-independent uptake of TRL in the Apoe4/4 Ldlrh/+ mice. Although we 
cannot eliminate the possibility that the DiI-labeled VLDL may have exchanged with the 
plasma lipoproteins in the recipient mice before it reached their hepatic surface, our results 
suggest that the sinusoidal enrichment of apoE does not necessarily ensure that apoE is 
transferred to TRL particles.
Jones et al recently demonstrated that mice with mutations in an adaptor protein involved in 
LDLR internalization can still clear VLDL.38 The authors suggested the possibility that 
VLDL remnants bind the LDLR on the hepatocyte cell surface but that their internalization 
may be mediated by another cell surface component that is also independent of LRP or 
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HSPG. Although the nature of this process is yet to be elucidated, the concept that remnants 
are handed from one cell surface molecule to the other while accumulating apoE molecules 
before their final internalization is attractive. Because LDLR serves as a regulator of apoE 
availability more than just a receptor, a higher affinity of apoE4 to the LDLR could delay the 
handing-off process, and thereby delay the clearance of remnants in the Apoe4/4Ldlrh/+ 
mice. In contrast, the reduced affinity of apoE2 for the LDLR, and to a lesser extent for 
HSPG, results in limited apoE2 sequestration on the surface of hepatocytes allowing their 
secretion into the circulation.39 As circulating lipoproteins in the Apoe2/2Ldlrh/+ mice have 
high apoE contents, a significant portion of the apoE2-enrichment of remnants may take 
place in the circulation and contribute to the subsequent remnant clearance in the liver of 
these mice. (A hypothetical model of interactions between apoE2 and apoE4 with the LDLR 
within the sinusoidal space is presented in supplemental Figure IX).
The genetic interaction between the apoE-isoforms and LDLR gene expression observed in 
mice translates well to humans, although not completely. For instance humans with APOE*4 
have elevated LDL remnants and Apoe4/4Ldlrh/+ mice accumulate VLDL remnants.12 
Nevertheless, an enhanced sequestration but delayed clearance of VLDL could prolong their 
exposure to surface bound lipases which could then accelerate lipolysis and conversion of 
VLDL to smaller remnants in the livers expressing apoE4 of both species. In contrast, 
limited interaction of apoE2 with the LDLR enhances VLDL clearance and reduces remnant 
production in apoE2 livers.21,40 Consequently, the overall degrees of reduction in LDL-
cholesterol resulting from the increase in LDLR expression in humans is likely to be apoE-
isoform–dependent; with more pronounced reduction in individuals with apoE2 but lesser 
reduction with apoE4.
Supplementary Material
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A, Secretion of apoE from primary hepatocytes isolated from Apoe2/2, Apoe3/3, Apoe4/4 
(left), and from Apoe4/4Ldlr−/−, Apoe4/4, Apoe4/4Ldlrh/+ (right) mice into the culture 
medium. Cell-associated apoE (B) and the ratio of apoE in the medium/cell-associated (C) 
from the above primary hepatocytes. D, Effects of heparinase on apoE secretion from 
Apoe4/4 and Apoe4/4Ldlrh/+ primary hepatocytes. E, Pulse chase analysis of Apoe4/4 and 
Apoe4/4 Ldlrh/+ hepatocytes. 35S-Methionine in cell-associated apoE (synthesis, time 0) 
during a 30-minute pulse and after 1-hour and 4-hour chase (retention) and in medium 
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(secretion) was determined using SDS-PAGE and phosphoimager. Values shown are the 
average of 3 wells. The experiment was repeated with a similar result.
**P≤0.005 and ***P≤0.0005.
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Immunohistochemical localization of apoE in the liver of mice. Anti-human LDLR staining 
in Apoe4/4 (A) and Apoe4/4 Ldlrh/+ (B). Staining for anti-human apoE in Apoe4/4 (C), 
Apoe4/4 Ldlrh/+ (D), Apoe3/3 (E), Apoe3/3Ldlrh/+ (F), Apoe2/2 (G), Apoe2/2Ldlrh/+ (H). 
(600X).
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Localization of apoE-GFP fusion proteins in the liver. Ad-apoE4-GFP (A, D), Ad-apoE3-
GFP (B, E), and Ad-apoE2-GFP (C, F) were injected into Apoe−/−Ldlrh/h (A, B, C) and 
Apoe−/− (D, E, F) mice. After 5 days liver sections (100 μm) were stained with 
Alexafluor633 labeled lectin (red), and GFP (green) signals were examined under a confocal 
microscopy (600×). VLDL isolated from Apoe−/− mice injected with Ad-apoE4-GFP or 
apoE2-GFP was injected into tail veins of Apoe−/−Ldlrh/h mice. ApoE4-GFP 5 minutes after 
i.v. injection (G), and apoE2-GFP (H).
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Localization and clearance of VLDL. A, DiI-labeled Apoe−/− VLDL was injected into 
Apoe2/2, Apoe2/2Ldlrh/+, Apoe3/3Ldlrh/+, and Apoe4/4Ldlrh/+ mice and fluorescent signals in 
plasma were measured at 2, 10, and 20 minutes. 2 minutes was taken as 100% (n=4). B 
through E, Livers at 20 minutes were analyzed by confocal microscopy for DiI-VLDL 
(yellow) and Alexafluor633 labeled lectin (blue): Apoe2/2 (B), Apoe2/2Ldlrh/+ (C), 
Apoe3/3Ldlrh/+ (D), Apoe4/4Ldlrh/+ (E). Below each panel are their lipoprotein profiles. 
Cholesterol (black), and relative amounts of apoE (green) and apoA1 (red) in the 
lipoproteins separated by fast protein liquid chromatography (FPLC) from plasma of mice 
before the injection of DiI-labeled VLDL.
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